Friday, September 30, 2022

561.316.3330

Biotechnology News Magazine

TransCure bioServices Welcomes Cathay Capital to Accelerate its Ambitious Growth

Latest Posts

City of Hope to Accelerate Immunotherapy Research & Treatment Innovation with $15 Mil Gift from Ted Schwartz Family

Ted Schwartz, who is now cancer free, achieved complete remission at City of Hope in 2020 with the center's leading CAR T cell therapy after a 16-year battle with lymphoma, provided the gift to City of Hope to advance treatment options that offer better outcomes and quality of life for people living with cancer.

Neurocrine Biosciences Appoints Dr Ingrid Delaet as Chief Regulatory Officer

Prior to joining Neurocrine Biosciences, Dr Ingrid Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals, which she joined in 2016.

Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification

“We believe that AstreAdept will be a game-changer,” explained Astrea Bioseparations’ CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHERO, a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].

At Pack Expo, Schreiner MediPharm to Debut Functional Labels Designed from More Sustainable Materials

Schreiner MediPharm advises he new label concepts are based on existing items in Schreiner MediPharm’s roster of functional labeling solutions.

Cathay Capital announced its investment in TransCure bioServices, alongside the management team and Financière Arbevel. With this transaction, TransCure bioServices will benefit from Cathay Capital’s healthcare expertise as well as its strategic, and financial support to accelerate its growth and global expansion.

Founded in 2012 and based in Archamps (Haute-Savoie, France), TransCure bioServices is a leading “one-stop-shop” preclinical contract research organization (CRO) specialized in advanced preclinical in vivo pharmacology with mouse models of fully reconstituted human immune system (HIS) or human-liver (Hu-liver) addressing various therapeutic areas including immuno-oncology, infectious diseases and inflammatory auto-immune diseases.

Thanks to a unique scientific expertise and proprietary humanization techniques, as well as a track-record of data accumulated over more than 10 years, TransCure bioServices has developed an unrivalled quality of services for a large and international customer base, providing c.70 large pharmas and biotech companies with a full spectrum of analytical testing services. TransCure bioServices capitalizes on fully reconstituted human immune system and human hepatic disease models with humanization rates that overperform market standards, allowing to perform tests with results reliability comparable to clinicals studies outcomes. With 80 employees, of which 20 PhDs, the company has witnessed double-digit organic growth over the last years reaching more than €10m of revenue and has recently been awarded with the AAALAC certification.

With strong experience in the healthcare sector and powered by its global platform, Cathay Capital’s investment will support TransCure bioServices in its next development phase, notably to accelerate its international expansion, the development of new mice model platforms, the increase of production capacities, as well as the strengthening of teams and to execute a focused external growth strategy.

Patrick Nef, PhD, co-founder and CEO of TransCure bioServices, said: “We have experienced a very high growth over the past 5-years, to become a truly international leading and highly specialized CRO in predictive in vivo pharmacology with humanized mouse models. Today, we welcome Cathay Capital as a timely and natural partner for us to build our next journey, as we will benefit from their experience in healthcare and know-how to accompany fast-growing companies internationally”

Fabien Wesse, Managing Partner at Cathay Capital, added: “We are very happy to work with Patrick Nef, Sébastien Tabruyn and the management team to support them in the company’s ambitious project. TransCure bioServices benefits from a unique scientific expertise on humanized mouse models across a variety of therapeutic areas, in a highly specialized rapidly growing preclinical market. We are delighted that they have chosen us as partners, and we will accompany them by leveraging our global platform, ecosystem, and commitment to the healthcare industry”

Latest Posts

Learn More

spot_img

Subscribe

spot_img

Our Sister Publication

Medical Device News Magazine